Jove
Visualize
Contact Us
  1. Home
  3. Characterisation Of Colorectal Cancers Showing Hypermethylation At Multiple Cpg Islands.
  1. Home
  3. Characterisation Of Colorectal Cancers Showing Hypermethylation At Multiple Cpg Islands.

Related Concept Videos

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands.

M van Rijnsoever1, F Grieu, H Elsaleh

  • 1Department of Surgery, University of Western Australia, Nedlands 6907, Australia.

Gut
|November 13, 2002

View abstract on PubMed

Summary
This summary is machine-generated.

The CpG island methylator phenotype (CIMP+) characterizes a distinct colorectal cancer (CRC) subgroup. CIMP+ CRC is linked to specific clinicopathological features and MTHFR gene variations, but not prognosis in early stages.

Related Experiment Videos

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Colorectal cancer (CRC) comprises heterogeneous subtypes.
  • The CpG island methylator phenotype (CIMP+) is a CRC subgroup with widespread CpG island methylation.
  • Clinicopathological and molecular features of CIMP+ CRC are not fully understood.

Purpose of the Study:

  • To investigate the clinicopathological and molecular characteristics of CIMP+ colorectal cancer.
  • To explore the prognostic significance of CIMP+ in stage II/III CRC.
  • To identify potential risk factors associated with CIMP+ development.

Main Methods:

  • Analysis of CpG island methylation in p16, MDR1, and MINT-2 in 275 stage II/III CRCs.
  • Correlation of CIMP+ status with clinicopathological variables and TP53/K-ras mutations.
  • Assessment of microsatellite instability and hMLH1 methylation.
  • Evaluation of MTHFR C677T polymorphism in relation to CIMP+ risk.

Main Results:

  • 32% of CRCs exhibited CIMP+, characterized by poor differentiation, fewer TP53 mutations, and proximal origin.
  • CIMP+ status did not impact prognosis in stage II/III CRC treated with surgery alone.
  • hMLH1 methylation was prevalent in microsatellite instability cases, often associated with CIMP+ and wild-type K-ras.
  • Heterozygous/homozygous C677T MTHFR polymorphism increased CIMP+ CRC risk (OR 2.17).

Conclusions:

  • CIMP+ defines a distinct subgroup of colorectal cancers with unique phenotypic features.
  • CIMP+ CRC is associated with specific molecular alterations and demographic factors.
  • Further research into CIMP+ CRC may reveal targeted therapeutic strategies.